Gene therapy company Krystal Biotech Inc (NASDAQ:KRYS) on Tuesday announced its plans to launch USD100m common stock in underwritten public offering .

The company plans to provide the underwriters with a 30-day option to purchase an additional 15% of the shares of its common stock offered in the public offering.

Net proceeds from this offering, together with its existing cash, cash equivalents and short-term investments, may be used by the company to complete the ongoing pivotal trial of B-VEC for DEB, advance KB105 in TGM1-deficient icthyosis, develop KB104 for Netherton syndrome and KB407 for cystic fibrosis, accelerate the emerging respiratory pipeline, complete a good manufacturing practices certified manufacturing facility, working capital, general corporate purposes, research and development expenses as well as capital expenditures.

Subject to market and other conditions, there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Goldman Sachs & Co. LLC, Cowen and Evercore ISI are acting as joint book-running managers for the offering.